RxDoctor Payments Data

Evan Freedman, DO

Pain Medicine · Sun City West, AZNPI 1184835613

Payments from drug & device makers

$5,200in general payments, 2019–2025

Across 121 payments — averaging $42.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$473
  • Nevro Corp.$312
  • Saluda Medical Americas, Inc.$189
  • Biodelivery Sciences International, Inc.$169
  • Medtronic$150
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,200 in reported general payments places this provider in the 55th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$494,736
Medicare patients
476
Services billed
28,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina33$42,774
BelbucaBuprenorphine Hcl45$41,673
Xtampza ErOxycodone Myristate41$35,693
OxycontinOxycodone Hcl47$27,250
Aimovig AutoinjectorErenumab-Aooe19$17,985
Buprenorphine60$13,986
MovantikNaloxegol Oxalate26$11,119
Emgality SyringeGalcanezumab-Gnlm12$8,610
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen276$8,161
LinzessLinaclotide14$7,739
ButransBuprenorphine13$6,822
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen248$5,501
Oxycodone Hcl230$3,869
Fentanyl32$3,021
Morphine Sulfate ErMorphine Sulfate107$3,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$114$77,36686 claims
AbbVieBotox, Linzess$110$50,51447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Sun City West

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →